News
If a higher body weight is affecting your ability to get around, or you have joint pain from arthritis, it can impair your ...
In the first head-to-head trial of its kind, people with obesity who took tirzepatide (sold under the brand names Mounjaro and Zepbound) lost more weight and inches from their waist than those who ...
While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...
Weight loss drugs have been pitted against each other in a first of its kind head-to-head trial. Mounjaro and Wegovy were put ...
For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...
The U.S. Food and Drug Administration (FDA) has issued a warning to patients and healthcare professionals regarding the use ...
For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...
14h
The Print on MSNMounjaro vs Wegovy: Guess which obesity drug outperformed the other by a mile in head-to-head trialBoth medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended ...
GLP-1RAs have grown massively in recent years following the release of Novo Nordisk’s semaglutide, marketed as Ozempic in type 2 diabetes and Wegovy in obesity, and Eli Lilly’s tirzepatide, marketed ...
Meghan Trainor changed a certain lyric in "All About That Bass" during a May 10 performance in Huntington Beach, Calif.
WGN’s Dina Bair has the latest on new medical information, including: Study: Mounjaro helped people achieve more weight loss ...
19h
Study Finds on MSNWeight Loss Showdown: Mounjaro (Tirzepatide) Trounces Wegovy in Head-to-Head TrialIn a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results